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occlusive cuff. The limbs were hyperperfused through arte-
rial access devices with a pump, producing a nonpulsatile
waveform at 200% to 300% of the mean arterial pressure
(MAP). This was performed intermittently in sessions of 24
to 36 hours and up to a maximum of 74 hours. The primary
end point was avoidance of major amputation. The second-
ary end points were the clinical improvements in rest pain,
ulcer healing, and claudication distance. The objective find-
ings include infrared thermography and ultrasound imag-
ing parameters of the limb.
Results: 39 of 40 connections developed flows 4 to 8
times those supplied to the limb by the normal cardiac
output. There was a progressive decrease in peripheral
resistance. All patients developed a pain-free, warm foot or
handwhilst on the pump in the short-term. In the longterm
at a mean of 22 months (12-54 months), eight of 20
patients (40%) had avoided major amputation and four
more had a delay in amputation of an average of 4 months.
The ankle-brachial index changed from 0.11  0.23 to
0.61 0.38 (P .05). Bleeding, infection, and removal of
the access systems and poor patient selection resulted in the
failures.
Conclusions: In selected cases major amputation may
be avoided by augmenting the collateral circulation of
ischemic limbs using an extracorporeal cardiac pump, oc-
cluding balloons and with an access system providing inter-
mittent pump connections.
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Objectives: In 2009 the Society for Vascular Surgery
(SVS) developed Objective Performance Goals (OPGs) to
assess the safety and efficacy of endovascular treatments of
critical limb ischemia (CLI). We evaluated Laser-assisted
angioplasty (LAA), using the OPGs
Methods: All patients that underwent LAA to treat
CLI between January 2006 and May 2010 were analyzed.
The 30 day safety endpoints of Major Adverse Cardiac
Event (MACE) (i.e. Postoperative Death (POD), Myocar-
dial Infarction (MI ) and Cerebrovascular Accident (CVA),
Amputation rate and Major Adverse Limb Event (MALE)
rate (i.e. thrombosis, thrombectomy, and bypass) were
calculated. The efficacy endpoints were calculated using
Kaplan-Meier life table analysis. These included MALE 
POD, Amputation Free Survival (AFS), and any Re-inter-
vention or above ankle Amputation and Stenosis /occlu-
sion (RAS) calculated at one year. Subsequently, a compar-
ison with the SVSOPGs was made using the student T test.
Results: : Laser assisted angioplasty was used to treat
82 limbs with CLI. The mean age was 72.8 years, with a
mean follow up of 19 months. Tissue loss and gangrene
were the most common indications, in 67 (81.2%) of the
limbs. Safety endpoints were: mortality rate 2.6%, MACE
rate 3.9%, amputation rate 2.4%, and MALE rate of 9.7%.
Efficacy endpoints were MALE  POD 84.1%, Amputa-
tion Free Survival 84.1%, and RAS 39%.Our study cohort
was compared to the SVS OPGs using the Student T test;
MACE 3.9% vs. 5.1% (P  .72), 30 day amputation rate
2.4% vs. 1.3% (P  .43), MALE 9.7% vs. 4.6% (P  .06).
One year outcomes: MALEPOD 84.1% vs. 76.9% (P 
.14), AFS 84.1% vs. 76.5% (P  .14), RAS 39% vs. 46.5%
(P  .21). No statistically significant difference was noted.
Conclusions: Our study demonstrates that the OPGs
are attainable in clinical practice. Moreover, LAAmeets the
safety and efficacy OPGs for endovascular treatment of
CLI.
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Objectives: Local vancomycin treatment has been
shown to decrease sternal wound complication rates.
Whether a similar effect can be achieved at other surgical
sites is unknown. This study investigates the effect of local
vancomycin on inguinal wound complication rates follow-
ing vascular procedures.
Methods: Retrospective analysis was performed on
646 patients who underwent open infra-inguinal and hy-
brid endovascular procedures between 2006 and 2011.
Patients received either pre-operative systemic antibiotics
alone (Group A) or in conjunction with intra-operative
wound application of vancomycin powder and irrigation
(Group B). Wound site infection and dehiscence over a
30-day period were recorded. Fisher exact test and multi-
variate regression analyses were performed.
Results: There were 424 patients in Group A and 222
patients in Group B. Both groups had similar demographics
and distribution of vascular procedures. There was no
significant difference in the 30-day incidence of superficial
and deep wound infections (OR: 0.72, P  .19) or dehis-
cence (OR: 1.2, P  .46) between the two groups after
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